Clinical Trial Update: Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing a Phase 1/Phase 2 study of sacituzumab govitecan plus anlotinib for metastatic triple-negative breast cancer; the trial status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING